Vivek Subbiah: So honored to Chair the AACR PLENARY session on April 10th, 2024 at AACR24 San Diego
Vivek Subbiah shared a post on X:
“ANNOUNCEMENT!
MARK your calendars! So honored to Chair the AACR PLENARY session on April 10th, 2024 at AACR24 San Diego.
Session: AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, & Improving Trial Design.
Save the date for this groundbreaking session with a fantastic speaker lineup: Anant Madabhushi, Maryellen Giger, Mia Levy, Thomas Clozel!”
Sign up.
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023